Results 111 to 120 of about 735,523 (289)

Multimodal Autonomic Biomarkers Predict Phenoconversion in Pure Autonomic Failure

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Pure autonomic failure (PAF) presents with autonomic failure without other neurological features. A third develop central neurological features, fulfilling criteria for multiple system atrophy (MSA) and Lewy body diseases (LBD), including Parkinson's disease and Dementia with Lewy bodies.
S. Koay, E. Vichayanrat, F. Bremner, F. Valerio, R. Mackenzie, G. Chiaro, G. Ingle, P. McNamara, L. Watson, J. N. Panicker, M. P. Lunn, C. Mathias, V. Iodice   +12 more
wiley   +1 more source

Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. [PDF]

, 2018
Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC).
Dicker, Adam P., Lu, Bo, McCall, Neal S.
core   +1 more source

Exploring if Longitudinal Changes on PET Imaging Can Serve as a Biomarker for Stiff Person Syndrome Spectrum Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify metabolic patterns in the brain and musculoskeletal system of stiff person syndrome spectrum disorders (SPSD) patients over time using PET imaging and evaluate the impact of immune therapy on metabolic activity as a surrogate for treatment response.
Munther M. Queisi, Samantha N. Roman, Mohammad S. Sadaghiani, Lilja B. Solnes, Scott D. Newsome   +4 more
wiley   +1 more source

Response of Syngeneic Murine Lymphomata to Immunotherapy in Relation to the Antigenicity of the Tumour [PDF]

, 1972
Iris B. Parr
openalex   +1 more source

Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE). Methods Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF ...
Albert Aboseif, Georgios Mangioris, Binxia Yang, Vanessa K. Pazdernik, Jeffrey W. Britton, Divyanshu Dubey, Eoin P. Flanagan, Sarosh R. Irani, Gregory S. Day, Charles L. Howe, A. Sebastian López‐Chiriboga, Andrew McKeon, John R. Mills, Yahel Segal, Michel Toledano, Ivana Vodopivec, Sean J. Pittock, Anastasia Zekeridou   +17 more
wiley   +1 more source

TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. [PDF]

, 2019
Tumor antigen-driven selection may expand T cells having T cell receptors (TCRs) of shared antigen specificity but different amino acid or nucleotide sequence in a process known as TCR convergence. Substitution sequencing errors introduced by TCRβ (TCRB)
Conroy, Jeffrey, Fong, Lawrence, Looney, Timothy John, Lowman, Geoffrey, Morrison, Carl, Oh, David, Topacio-Hall, Denise, Zhang, Li   +7 more
core  

Inhibition of Glutamine Metabolism Attenuates Tumor Progression Through Remodeling of the Macrophage Immune Microenvironment

Advanced Biology, EarlyView.
The prodrug strategy used in this study offers new promise for cancer metabolism‐based therapies. JHU083, a prodrug that, when cleaved by protease in the tumor microenvironment, yields the glutamine antagonist DON. JHU083 inhibits tumor growth by targeting glutamine‐addicted cancer cells and suppressing glutamine‐dependent M2 macrophages, leading to a ...
Tianhe Li, Sepehr Akhtarkhavari, Sumeng Qi, Jiawei Fan, Tu‐Yung Chang, Yao‐An Shen, JinMing Yang, Barbara S. Slusher, Ie‐Ming Shih, Stephanie Gaillard, Tian‐Li Wang   +10 more
wiley   +1 more source

Intersection Between Local Anesthetics and Cancer Biology: What Now? Where Are We Going?

Advanced Biology, EarlyView.
Local anesthetics (LAs), widely used in anesthesia, may also play a role in cancer treatment by inhibiting tumor growth, reducing metastasis, and enhancing immune responses. They modulate key pathways like AKT/mTOR and RAS/ERK while affecting angiogenesis and tumor innervation and the immune response.
Eduardo Nunez‐Rodriguez, Hao Zhang, Dhananjay Sah, Juan P. Cata   +3 more
wiley   +1 more source

NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence

Cell Death Discovery
Gefitinib is one of the most extensively utilized epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for treating advanced lung adenocarcinoma (LUAD) patients harboring EGFR mutation.
Shuman Zhen, Yunlong Jia, Yan Zhao, Jiali Wang, Boyang Zheng, Tianxu Liu, Yuqing Duan, Wei Lv, Jiaqi Wang, Fan Xu, Yueping Liu, Yi Zhang, Lihua Liu   +12 more
doaj   +1 more source

Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. [PDF]

, 1977
M B McIllmurray, M. J. Embleton, W G Reeves, M J Langman, Malcolm Deane   +4 more
openalex   +1 more source